(via TheNewswire)

Toronto, Ontario – TheNewswire - A ugust 12 , 2026 – NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), today announced that the Japanese Patent Office has granted the company a patent for its pharmacological combination titled “Compositions and Methods for Potentiating Derivatives of 4-Aminophenols.”

The newly granted Japanese patent covers pharmaceutical compositions and methods comprising proprietary combinations of 4-aminophenols derivatives (including paracetamol) and N-acylethanolamines. These combinations are designed to enhance the analgesic and antipyretic performance of 4-aminophenol-based therapies. NeuroThera believes this synergistic approach may enable lower effective dosing while helping to mitigate dose ‑ related side ‑ effect concerns associated with established treatments.

This patent further strengthens NeuroThera’s expanding intellectual property portfolio reinforcing protection for its combination-therapy platforms designed to optimize and modernize standard treatments for pain, fever, and related conditions.

The addition of Japanese patent coverage marks an important strategic milestone as the Company advances its next ‑ generation therapeutic innovations across global markets.

NeuroThera Labs continues to advance its therapeutic platforms with the goal of delivering safe, effective, and accessible treatments to patients worldwide.

About NeuroThera Labs Inc.

NeuroThera Labs Inc. (TSXV: NTLX) is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

For further information, please contact:

Michal Efraty

IR Manager

NeuroThera Labs Inc.

Telephone: +972-3-7617108

Email: michal@efraty.com

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Notice on Forward-Looking Statements

This news release contains statements that constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release.

Forward-looking information in this news release includes statements regarding the potential benefits of the patented combinations, including their potential to enhance the effects of 4-aminophenol derivatives, potentially enable lower effective doses and address dose-related side effects, as well as the potential for NeuroThera’s proprietary combination platforms to improve established therapies for pain, fever and related conditions; the Company's plans to advance its next-generation therapeutic innovations and therapeutic platforms across global markets; and the Company's goal of developing and delivering safe, effective and accessible treatments to patients worldwide, including novel therapeutics for central nervous system disorders and other underserved conditions.

These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking information necessarily involves known and unknown risks and uncertainties, which may cause the Company's actual performance and results to differ materially from any projections of future performance or results expressed or implied by such forward-looking information. Such factors include, without limitation the risks described in the Company's continuous disclosure documents filed on SEDAR+ ( www.sedarplus.ca ).

The Company does not undertake any obligation to update or revise any forward-looking information, except as required by applicable securities laws.

Copyright (c) 2026 TheNewswire - All rights reserved.